Magic mushroom compound tested for PTSD relief in small study
NCT ID NCT06407635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether psilocybin (the active ingredient in magic mushrooms) can safely help adults with long-term PTSD who are already taking antidepressants. Twenty participants will receive psilocybin, and some will also get trauma-focused talk therapy. The goal is to see if psilocybin reduces PTSD symptoms and improves well-being, while checking for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TRAUMATIC STRESS DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins Center for Psychedelic and Consciousness Research
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A targeted talk therapy aims to quiet the echoes of trauma
- Can a therapy that tackles both PTSD and everyday stress help those most at risk?
- Brain zaps boost therapy for PTSD in troops with head injuries
- Can a 6-Session CBT approach outperform traditional talk therapy for PTSD?
- Could MDMA help heal PTSD in soldiers? new trial investigates
- Ecstasy-Assisted therapy shows promise for veterans haunted by war